Phase I Study of Decitabine and Haplo-identical Natural Killer Cells in Acute Myeloid Leukemia (AML)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Aldesleukin (Primary) ; Decitabine (Primary) ; Natural killer cell therapy (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 03 Apr 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
- 03 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Dec 2016 Status changed from suspended to recruiting.